Esophageal Diseases
Welcome,         Profile    Billing    Logout  
 128 Companies   121 Products   121 Products   104 Mechanisms of Action   7 Trials   1812 News 


«12...345678910111213...3637»
  • ||||||||||  Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
    New P2 trial:  Movantik for Opioid-Related Esophageal Disorders (clinicaltrials.gov) -  Dec 20, 2016   
    P2,  N=50, Not yet recruiting, 
  • ||||||||||  Trial primary completion date:  Prevalence of Dysplasia of the Gastric Cardia (clinicaltrials.gov) -  Dec 20, 2016   
    P=N/A,  N=170, Active, not recruiting, 
    Trial primary completion date: Jan 2017 --> Jun 2017
  • ||||||||||  Trial completion, Trial primary completion date:  EoE(Eosinophilic Esophagitis) (clinicaltrials.gov) -  Dec 16, 2016   
    P=N/A,  N=10, Completed, 
    Phase classification: P4 --> P1 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Apr 2016
  • ||||||||||  gefitinib / Generic mfg.
    Trial primary completion date, Metastases:  Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer (clinicaltrials.gov) -  Dec 13, 2016   
    P2,  N=70, Completed, 
    Trial primary completion date: May 2008 --> Feb 2007 Trial primary completion date: Oct 2009 --> Aug 2007
  • ||||||||||  Trial completion, Enrollment change:  Pillars4Life Trial (clinicaltrials.gov) -  Dec 7, 2016   
    P=N/A,  N=284, Completed, 
    Trial primary completion date: Jan 2009 --> Jul 2005 Active, not recruiting --> Completed | N=400 --> 284
  • ||||||||||  Enrollment change, Trial termination:  RELIEF Europe Study (clinicaltrials.gov) -  Dec 6, 2016   
    P4,  N=7, Terminated, 
    Active, not recruiting --> Completed | N=400 --> 284 N=100 --> 7 | Recruiting --> Terminated; Insufficient enrollment
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
    Trial primary completion date:  Effects of Victoza (clinicaltrials.gov) -  Dec 1, 2016   
    P1,  N=72, Active, not recruiting, 
    Not yet recruiting --> Completed Trial primary completion date: Oct 2016 --> Mar 2017
  • ||||||||||  Trial completion:  CoFAR5: Eosinophilic Esophagitis Databank (clinicaltrials.gov) -  Nov 14, 2016   
    P=N/A,  N=709, Completed, 
    Trial primary completion date: Sep 2016 --> Jan 2017 Active, not recruiting --> Completed
  • ||||||||||  AMG 337 / ImmunityBio, Amgen
    Trial termination, Trial primary completion date:  Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors (clinicaltrials.gov) -  Nov 10, 2016   
    P2,  N=60, Terminated, 
    Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
  • ||||||||||  Trial primary completion date:  Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas (clinicaltrials.gov) -  Nov 9, 2016   
    P=N/A,  N=20, Recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Amgen decision following interim review of efficacy and safety data from the AMG 337 program. Trial primary completion date: Sep 2016 --> Dec 2016
  • ||||||||||  Trial primary completion date, Surgery:  Prevention of Post-operative Pneumonia (POPP) (clinicaltrials.gov) -  Oct 31, 2016   
    P2/3,  N=330, Active, not recruiting, 
    Recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  indomethacin / Generic mfg.
    Trial primary completion date, Combination therapy:  PIFA: Phase I Platinum Based Chemotherapy Plus Indomethacin (clinicaltrials.gov) -  Oct 26, 2016   
    P1,  N=18, Recruiting, 
    Enrolling by invitation --> Completed | Trial primary completion date: Sep 2017 --> Jan 2016 Trial primary completion date: Feb 2016 --> Dec 2018
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  DysphagCerv: Dysphagia and Cervical Spine Disorders in Patients With Brain Lesions (clinicaltrials.gov) -  Oct 26, 2016   
    P1,  N=70, Completed, 
    Trial primary completion date: Feb 2016 --> Dec 2018 Recruiting --> Completed | N=100 --> 70 | Trial primary completion date: Nov 2015 --> Oct 2016
  • ||||||||||  Trial completion, Trial primary completion date:  Cologne Esophageal Response Prediction Study (CERP-Study) (clinicaltrials.gov) -  Oct 21, 2016   
    P=N/A,  N=80, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Apr 2015
  • ||||||||||  Trial completion, Trial primary completion date:  Endoscopic Evaluation After Esophagectomy (clinicaltrials.gov) -  Oct 18, 2016   
    P=N/A,  N=10, Completed, 
    N=124 --> 28 Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Oct 2016
  • ||||||||||  cisplatin / Generic mfg.
    Trial primary completion date, Biopsy:  CHFR Methylation Status Esophageal Cancer Study (clinicaltrials.gov) -  Oct 13, 2016   
    P2,  N=56, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Oct 2016 Trial primary completion date: Jun 2015 --> Jun 2014